drugset / Trial / NCT00832624

The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)

NCT00832624

Phase 4 Terminated 10 enrolled Merck Sharp & Dohme LLC
Non-randomizedSingle-groupOpen-labelTreatment

Summary

to assess the effect of treatment with Sitagliptin (MK0431) on HbA1c (Hemoglobin A1c) and the safety and tolerability of Sitagliptin.

Timeline

Start
2008-11-26
Primary completion
2009-09-02
Completion
2009-09-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Sitagliptin Small molecule 100 mg